LC
BMY icon

Luminist Capital’s Bristol-Myers Squibb BMY Stock Holding History

Luminist Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71K Buy
+47
New +$2.7K ﹤0.01% 314

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Luminist Capital's BMY Position: Q2 2026 in Review

Luminist Capital opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 47 shares worth $2.71K. The stake represents ﹤0.01% of the portfolio and ranks #314 among its holdings.

2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Luminist Capital held 47 shares of Bristol-Myers Squibb worth $2.71K as of Q2 2026.
  • Bristol-Myers Squibb was a new Luminist Capital position in Q2 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Luminist Capital's portfolio in Q2 2026, its #314 holding.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Luminist Capital's 13F filing for Q2 2026, filed 7 Aug 2026.